Skip to main content
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · TARS ISIN · US87650L1035 US Manufacturing
Open in API
Filings indexed 576 across all filing types
Latest filing 2023-11-17 Capital/Financing Update
Country US United States of America
Listing US TARS

About Tarsus Pharmaceuticals, Inc.

https://www.tarsusrx.com/

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for diseases with limited treatment options. The company's initial focus is on eye care. Its lead product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, is the first and only FDA-approved treatment for Demodex blepharitis. Tarsus is also advancing a pipeline of potential treatments for other conditions with high unmet needs, including ocular rosacea, Lyme disease prevention, and other indications across dermatology and infectious diseases.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2023
Capital/Financing Update Classification · 95% confidence The document is a letter from Tarsus Pharmaceuticals to the SEC requesting acceleration of the effectiveness of a Registration Statement on Form S-3. It references a filing made on November 9, 2023, and requests the SEC to expedite the process. The content is a formal correspondence related to a capital raising registration statement, not a financial report or earnings release. The document is short (1498 characters) and is a procedural request rather than a report or announcement of results. This fits the category of Capital/Financing Update (CAP), as it relates to the registration statement for securities issuance and the acceleration request for the offering process.
2023-11-17 English
Regulatory Filings 2023
Regulatory Filings
2023-11-16 English
Regulatory Filings 2023
Regulatory Filings
2023-11-15 English
FORM S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC by Tarsus Pharmaceuticals, Inc. It is a registration statement under the Securities Act of 1933 for the purpose of registering securities for sale, including common stock, preferred stock, debt securities, warrants, and units. The document includes a base prospectus and mentions prospectus supplements for specific offerings. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement or a certification, so it is not RPA or RNS. Hence, the correct classification is CAP with high confidence.
2023-11-09 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 9, 2023, by Tarsus Pharmaceuticals, Inc. It specifically mentions "Item 2.02 Results of Operations and Financial Condition" and states that a press release with the company's results for the three months ended September 30, 2023, is attached as Exhibit 99.1. The document itself is a current report providing an update on quarterly financial results, not a full quarterly report or annual report. The length is 3645 characters, which is relatively short and consistent with a current report or earnings release. The content focuses on announcing financial results via a press release rather than providing detailed financial statements or management discussion. Therefore, this document fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only.
2023-11-09 English
10-Q
Interim / Quarterly Report Q3 2023
2023-11-09 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.